ProCE Banner Activity

My Thoughts on the Recent Advances in the Management of β-Thalassemia

Clinical Thought

Gain insights on recent developments in the care of patients with &beta -thalassemia along with ongoing clinical issues and emerging therapies to address them.

Released: November 12, 2020

Expiration: November 11, 2021

No longer available for credit.

Share

Faculty

Janet L. Kwiatkowski

Janet L. Kwiatkowski, MD, MSCE

Professor of Pediatrics
Perelman School of Medicine of the University of Pennsylvania
Director, Thalassemia Program
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Supporters

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Janet L. Kwiatkowski, MD, MSCE

Professor of Pediatrics
Perelman School of Medicine of the University of Pennsylvania
Director, Thalassemia Program
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania

Janet L. Kwiatkowski, MD, MSCE, has disclosed that she has served on advisory boards/as a consultant for Agios, Bluebird Bio, and Celgene; has received consulting fees from Imara and Silence Therapeutics; and has received funds for research support from ApoPharma, Bluebird Bio, Novartis, Sangamo, and Terumo BCT.